Lymphoblastic Leukemia

SAN DIEGO — Marlise R. Luskin, MD, MSCE, speaks with Healio about findings from the phase 3 randomized Alliance A041501 trial.

In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting that examined the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia.

Obecabtagene autoleucel conferred durable benefit to certain patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to results of the phase 1B/phase 2 FLEIX study presented at ASCO Annual Meeting.

The FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a chemotherapy regimen to treat certain adults or children with acute lymphoblastic leukemia or lymphoblastic lymphoma.

Having cleared a major hurdle by completing active treatment, cancer survivors often find themselves unprepared for the ongoing challenges they face during survivorship.